Downregulated expression of TSHR is associated with distant metastasis in thyroid cancer

Liu,Tianrun; Men,Qianqian; Su,Xuan; Chen,Weichao; Zou,Lan; Li,Qiuli; Song,Ming; Ouyang,Dian; Chen,Yanfeng; Li,Zhaoqu; Fu,Xiaoyan; Yang,Ankui

doi:10.3892/ol.2017.7122

Downregulated expression of TSHR is associated with distant metastasis in thyroid cancer

Authors:
- Tianrun Liu
- Qianqian Men
- Xuan Su
- Weichao Chen
- Lan Zou
- Qiuli Li
- Ming Song
- Dian Ouyang
- Yanfeng Chen
- Zhaoqu Li
- Xiaoyan Fu
- Ankui Yang
View Affiliations

Affiliations: Department of Otorhinolaryngology Head and Neck Surgery, The Sixth Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510655, P.R. China, Graceland Medical Center, The Sixth Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510655, P.R. China, Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: October 3, 2017 https://doi.org/10.3892/ol.2017.7122
Pages: 7506-7512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In differentiated thyroid cancer (DTC), the association between thyroid‑stimulating hormone receptor (TSHR) and metastasis, and the underlying molecular mechanisms remain unclear. The role of TSHR in the epithelial‑mesenchymal transition (EMT) has not yet been reported, to the best of our knowledge. In the present study, the role of TSHR in the distant metastasis of DTC was investigated. TSHR was significantly downregulated in well‑differentiated thyroid cancer cells and tissues, and a lack of TSHR promoted thyroid cancer cell invasion and metastasis by inhibiting the EMT of thyroid cancer cells. In addition, the prognostic value of TSHR in thyroid cancer was analyzed. Immunohistochemical analysis of 172 DTC tissues revealed that a lack of expression of TSHR was associated with distant metastasis and a poor survival rate. Multivariate analyses demonstrated that TSHR expression was a significant prognostic factor for distant metastasis and survival time. The results from the present study demonstrated that TSHR inhibits metastasis through regulating EMT in vitro, and that a lack of expression of TSHR is a significant independent factor affecting distant metastasis and poor prognosis in DTC.

View Figures

View References

1	Nikiforov YE and Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
2	Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME and Chomienne C: Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer. Clin Cancer Res. 18:442–453. 2012. View Article : Google Scholar : PubMed/NCBI
3	Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP and Shaha AR: Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 197:191–197. 2003. View Article : Google Scholar : PubMed/NCBI
4	Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE and Roger PP: Regulation of thyroid cell proliferation by TSH and other factors: A critical evaluation of in vitro models. Endocr Rev. 22:631–656. 2001. View Article : Google Scholar : PubMed/NCBI
5	Lu C, Zhao L, Ying H, Willingham MC and Cheng SY: Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology. 151:1929–1939. 2010. View Article : Google Scholar : PubMed/NCBI
6	Davies T, Marians R and Latif R: The TSH receptor reveals itself. J Clin Invest. 110:161–164. 2002. View Article : Google Scholar : PubMed/NCBI
7	Cannito S, Novo E, di Bonzo LV, Busletta C, Colombatto S and Parola M: Epithelial-mesenchymal transition: From molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal. 12:1383–1430. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
9	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
10	Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al: EMT and dissemination precede pancreatic tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
11	Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, et al: Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 13:508–514. 2007. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Krook KA, Fedewa SA and Chen AY: Prognostic indicators in well-differentiated thyroid carcinoma when controlling for stage and treatment. Laryngoscope. 125:1021–1027. 2015. View Article : Google Scholar : PubMed/NCBI
14	Gandolfi G, de Biase D, Sancisi V, Ragazzi M, Acquaviva G, Pession A, Piana S, Tallini G and Ciarrocchi A: Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases. Endocr Relat Cancer. 21:L23–L26. 2014. View Article : Google Scholar : PubMed/NCBI
15	Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A and Sancisi V: TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol. 172:403–413. 2015. View Article : Google Scholar : PubMed/NCBI
16	Cancer Genome Atlas Research Network: Integrated genomic characterization of papillary thyroid carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
17	Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, et al: Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: A marker of malignancy and a cause of gene silencing. Cancer Res. 63:2316–2321. 2003.PubMed/NCBI
18	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
19	Deng X, Wu B, Xiao K, Kang J, Xie J, Zhang X and Fan Y: MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3. Cell Physiol Biochem. 35:71–82. 2015. View Article : Google Scholar : PubMed/NCBI
20	Hardin H, Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu XM, Harrison AD, Chen H and Lloyd RV: The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 184:2342–2354. 2014. View Article : Google Scholar : PubMed/NCBI
21	Braun J, Hoang-Vu C, Dralle H and Hüttelmaier S: Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 29:4237–4244. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhang Z, Liu ZB, Ren WM, Ye XG and Zhang YY: The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med. 30:856–862. 2012. View Article : Google Scholar : PubMed/NCBI
23	Feng X, Wang Z, Fillmore R and Xi Y: MiR-200, a new star miRNA in human cancer. Cancer Lett. 344:166–173. 2014. View Article : Google Scholar : PubMed/NCBI
24	Jeon MJ, Kim TY, Kim WG, Han JM, Jang EK, Choi YM, Song DE, Yoon JH, Chung KW, Hong SJ, et al: Differentiating the location of cervical lymph node metastasis is very useful for estimating the risk of distant metastases in papillary thyroid carcinoma. Clin Endocrinol (Oxf). 81:593–599. 2014. View Article : Google Scholar : PubMed/NCBI
25	Middendorp M and Grünwald F: Update on recent developments in the therapy of differentiated thyroid cancer. Semin Nucl Med. 40:145–152. 2010. View Article : Google Scholar : PubMed/NCBI
26	Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, et al: Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 8:737–744. 1998. View Article : Google Scholar : PubMed/NCBI
27	Sugitani I and Fujimoto Y: Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab. 95:4576–4583. 2010. View Article : Google Scholar : PubMed/NCBI